NB100-127

Sun D, Stopka-Farooqui U, Barry S, Aksoy E, Parsonage G, Vossenkämper A, Capasso M, Wan X, Norris S, Marshall JL, Clear A, Gribben J, MacDonald TT, Buckley CD, Korbonits M, Haworth O
Cell reports 2019 Apr 30;27(5):1461-1471.e4

Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.

Yamamoto R, Robert Shima K, Igawa H, Kaikoi Y, Sasagawa Y, Hayashi Y, Inoshita N, Fukuoka H, Takahashi Y, Takamura T
Endocrine journal 2018 Oct 29;65(10):1061-1067

Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues.

Ozkaya HM, Comunoglu N, Sayitoglu M, Keskin FE, Firtina S, Khodzhaev K, Apaydin T, Gazioglu N, Tanriover N, Oz B, Kadioglu P
Pituitary 2018 Aug;21(4):335-346

Impact of AIP and inhibitory G protein alpha 2 proteins on clinical features of sporadic GH-secreting pituitary adenomas.

Ritvonen E, Pitkänen E, Karppinen A, Vehkavaara S, Demir H, Paetau A, Schalin-Jäntti C, Karhu A
European journal of endocrinology 2017 Feb;176(2):243-252

Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells.

Rotondi S, Modarelli A, Oliva MA, Rostomyan L, Sanita P, Ventura L, Daly AF, Esposito V, Angelucci A, Arcella A, Giangaspero F, Beckers A, Jaffrain-Rea ML
Molecular and cellular endocrinology 2016 May 5;426:61-72

Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.

Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, Giampietro A, Mormando M, Clear AJ, Doglietto F, Anile C, Maira G, Lauriola L, Rindi G, Roncaroli F, Pontecorvi A, Korbonits M, De Marinis L
European journal of endocrinology 2016 Feb;174(2):241-50

Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas.

Dénes J, Kasuki L, Trivellin G, Colli LM, Takiya CM, Stiles CE, Barry S, de Castro M, Gadelha MR, Korbonits M
PloS one 2015;10(2):e0117107

X-linked acrogigantism syndrome: clinical profile and therapeutic responses.

Beckers A, Lodish MB, Trivellin G, Rostomyan L, Lee M, Faucz FR, Yuan B, Choong CS, Caberg JH, Verrua E, Naves LA, Cheetham TD, Young J, Lysy PA, Petrossians P, Cotterill A, Shah NS, Metzger D, Castermans E, Ambrosio MR, Villa C, Strebkova N, Mazerkina N, Gaillard S, Barra GB, Casulari LA, Neggers SJ, Salvatori R, Jaffrain-Rea ML, Zacharin M, Santamaria BL, Zacharieva S, Lim EM, Mantovani G, Zatelli MC, Collins MT, Bonneville JF, Quezado M, Chittiboina P, Oldfield EH, Bours V, Liu P, W de Herder W, Pellegata N, Lupski JR, Daly AF, Stratakis CA
Endocrine-related cancer 2015 Jun;22(3):353-67

AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up.

Mian C, Ceccato F, Barollo S, Watutantrige-Fernando S, Albiger N, Regazzo D, de Lazzari P, Pennelli G, Rotondi S, Nacamulli D, Pelizzo MR, Jaffrain-Rea ML, Grimaldi F, Occhi G, Scaroni C
PloS one 2014;9(7):e101560

Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations.

Jaffrain-Rea ML, Rotondi S, Turchi A, Occhi G, Barlier A, Peverelli E, Rostomyan L, Defilles C, Angelini M, Oliva MA, Ceccato F, Maiorani O, Daly AF, Esposito V, Buttarelli F, Figarella-Branger D, Giangaspero F, Spada A, Scaroni C, Alesse E, Beckers A
Endocrine-related cancer 2013 Oct;20(5):753-66

Beta-catenin signaling induces CYP1A1 expression by disrupting adherens junctions in Caco-2 human colon carcinoma cells.

Kasai S, Ishigaki T, Takumi R, Kamimura T, Kikuchi H
Biochimica et biophysica acta 2013 Mar;1830(3):2509-16

Aip regulates cAMP signalling and GH secretion in GH3 cells.

Formosa R, Xuereb-Anastasi A, Vassallo J
Endocrine-related cancer 2013 Aug;20(4):495-505

Growth of an aggressive tumor during pregnancy in an acromegalic patient.

Kasuki L, Neto LV, Takiya CM, Gadelha MR
Endocrine journal 2012;59(4):313-9

Growth of an aggressive tumor during pregnancy in an acromegalic patient.

Kasuki L, Neto LV, Takiya CM, Gadelha MR
Endocrine journal 2012;59(4):313-9

MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro.

Trivellin G, Butz H, Delhove J, Igreja S, Chahal HS, Zivkovic V, McKay T, Patócs A, Grossman AB, Korbonits M
American journal of physiology. Endocrinology and metabolism 2012 Sep 15;303(6):E708-19

Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.

Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A, Igreja SC, Chapple JP, Jordan S, Lupp A, Schulz S, Ansorge O, Karavitaki N, Carlsen E, Wass JA, Grossman AB, Korbonits M
The Journal of clinical endocrinology and metabolism 2012 Aug;97(8):E1411-20

Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.

Kasuki Jomori de Pinho L, Vieira Neto L, Armondi Wildemberg LE, Gasparetto EL, Marcondes J, de Almeida Nunes B, Takiya CM, Gadelha MR
Neuroendocrinology 2011;94(1):39-48

The immunophilin-like protein XAP2 is a negative regulator of estrogen signaling through interaction with estrogen receptor α.

Cai W, Kramarova TV, Berg P, Korbonits M, Pongratz I
PloS one 2011;6(10):e25201

Developmental control of apoptosis by the immunophilin aryl hydrocarbon receptor-interacting protein (AIP) involves mitochondrial import of the survivin protein.

Kang BH, Xia F, Pop R, Dohi T, Socolovsky M, Altieri DC
The Journal of biological chemistry 2011 May 13;286(19):16758-67

Rabconnectin-3 is a functional regulator of mammalian Notch signaling.

Sethi N, Yan Y, Quek D, Schupbach T, Kang Y
The Journal of biological chemistry 2010 Nov 5;285(45):34757-64

Differential impact of tetratricopeptide repeat proteins on the steroid hormone receptors.

Schülke JP, Wochnik GM, Lang-Rollin I, Gassen NC, Knapp RT, Berning B, Yassouridis A, Rein T
PloS one 2010 Jul 22;5(7):e11717

Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of aip also in non-pituitary tumorigenesis.

Toledo RA, Mendonca BB, Fragoso MC, Soares IC, Almeida MQ, Moraes MB, Lourenço DM Jr, Alves VA, Bronstein MD, Toledo SP
Clinics (Sao Paulo, Brazil) 2010 Apr;65(4):407-15

Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications.

Jaffrain-Rea ML, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen JF, D'Innocenzo E, Barlier A, Giangaspero F, Esposito V, Ventura L, Arcella A, Theodoropoulou M, Naves LA, Fajardo C, Zacharieva S, Rohmer V, Brue T, Gulino A, Cantore G, Alesse E, Beckers A
Endocrine-related cancer 2009 Sep;16(3):1029-43

The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas.

Heliövaara E, Raitila A, Launonen V, Paetau A, Arola J, Lehtonen H, Sane T, Weil RJ, Vierimaa O, Salmela P, Tuppurainen K, Mäkinen M, Aaltonen LA, Karhu A
The American journal of pathology 2009 Dec;175(6):2501-7

Role of endogenous XAP2 protein on the localization and nucleocytoplasmic shuttling of the endogenous mouse Ahb-1 receptor in the presence and absence of ligand.

Pollenz RS, Wilson SE, Dougherty EJ
Molecular pharmacology 2006 Oct;70(4):1369-79

The aryl hydrocarbon (Ah) receptor transcriptional regulator hepatitis B virus X-associated protein 2 antagonizes p23 binding to Ah receptor-Hsp90 complexes and is dispensable for receptor function.

Hollingshead BD, Petrulis JR, Perdew GH
The Journal of biological chemistry 2004 Oct 29;279(44):45652-61

Subcellular localization of the aryl hydrocarbon receptor is modulated by the immunophilin homolog hepatitis B virus X-associated protein 2.

Petrulis JR, Hord NG, Perdew GH
The Journal of biological chemistry 2000 Dec 1;275(48):37448-53

No comments: Submit comment

Supportive validation

Submitted by: Novus Biologicals (provider)
Main image
Experimental details: Simple Western: AIP/ARA9 Antibody (35-2) [NB100-127] - Simple Western lane view shows a specific band for AIP/ARA9 in 0.5 mg/ml of Hek293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

Supportive validation

Submitted by: Novus Biologicals (provider)
Main image
Experimental details: Western Blot: AIP/ARA9 Antibody (35-2) [NB100-127] - Detection on HEK 293T/17 cells. Lane 1: IP ARA9, WB ARA9, Lane 2: WB ARA9 with whole cell lysate. Photo courtesy of Liling Zeng, Boston University.

Supportive validation

Submitted by: Novus Biologicals (provider)
Main image
Experimental details: Western Blot: AIP/ARA9 Antibody (35-2) [NB100-127] - Detection of Ara9 in mouse lung lysates (30ug) using NB 100-127 at 1:500 with a 1 second exposure.

Supportive validation

Submitted by: Novus Biologicals (provider)
Main image
Experimental details: Immunohistochemistry-Paraffin: AIP/ARA9 Antibody (35-2) [NB100-127] - AIP/ARA9 was detected in immersion fixed paraffin-embedded sections of human spleen using Mouse Anti-Human AIP/ARA9 (35-2) Monoclonal Antibody (Catalog # NB100-127) at 1:300 for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm in splenocytes.

Supportive validation

Submitted by: Novus Biologicals (provider)
Main image
Experimental details: Immunohistochemistry: AIP/ARA9 Antibody (35-2) [NB100-127] - Fig 1. Aryl hydrocarbon receptor interacting protein (AIP) immunostaining. A and B Examples of low AIP expression; C and D: Examples of high AIP expression; E Normal human pituitary staining with omitting primary antibody (negative control); F Normal human pituitary staining with AIP (positive control); Scale bar = 1000 um. Image collected and cropped by CiteAb from the following publication (http://dx.plos.org/10.1371/journal.pone.0117107) licensed under a CC-BY licence.

Supportive validation

Submitted by: Novus Biologicals (provider)
Main image
Experimental details: Flow Cytometry: AIP/ARA9 Antibody (35-2) [NB100-127] - Intracellular flow cytometric staining of 1 x 10^6 CHO (A) and MCF-7 (B) cells using AIP/ARA9 antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.